Bayer HealthCare and Activaero in inhaled treatment deal
This article was originally published in Scrip
Bayer HealthCare and German-based Activaero Technologies are to develop preclinical-stage compounds for inhaled treatments. The therapeutic targets and active ingredients have not been disclosed. Under the licensing and option agreement, Activaero will receive an upfront payment and milestone payments if Bayer HealthCare exercises its option; no further financial details were given. Dr Gerhard Scheuch, founder and CEO of Activaero believes that pulmonary administration of drugs has "a huge potential for the treatment of lung diseases and diseases which start in the lung". The company has two products on the market - AKITA, a patient-tailored controlled breathing system with a smartcard that records patient dosing parameters, and Watchhaler, a hand-held delivery system specifically for children. It says it also has other technologies for the controlled delivery of inhaled therapeutics in the clinical setting.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.